OMEGAVEN AND PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项先导性研究的具体目的是调查静脉注射(IV)鱼油(FO)是否可以在商业上获得，如Omeaven？(Fresenius Kabi)，1克/公斤/天，不超过24周，将安全地逆转或改善15名PNAC患者的肝病

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The specific aim of this pilot study is to investigate if intravenous (IV) fish oil (FO), commercially available as Omegaven? (Fresenius Kabi), at 1 gm/kg/d for no longer than 24 weeks, will safely reverse or ameliorate liver disease in 15 subjects with PNAC